A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants
Status:
Completed
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the effect of pirtobrutinib (LOXO-305) on
single oral dose of repaglinide (CYP2C8 substrate) when administered as multiple doses by
conducting the blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream
and how the body handles and eliminates pirtobrutinib (LOXO-305) in adult healthy
participants. The study will also evaluate the safety and tolerability of pirtobrutinib
(LOXO-305). The study is conducted in two periods. Participants will stay in this study for
up to 54 days.